Back to search results
NCT07594496

Prevalence and Clinical Manifestations of Cannabis Withdrawal in Hospitalized Patients With Hematological Malignancies Undergoing Bone Marrow Transplant (BMT) or Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Enrolling by Invitation
Not specifiedAges 18+Observational
Mayo Clinic
~300 participants
Updated 2026-05-18 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Prevalence of cannabis withdrawal
Measured over Up to 1 year
+1 more outcome measured

Conditions

Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm

Explore related trials

Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm

Where it's being run

1 sites across 1 states
Arizona1

Study leadership

  • Osama A. Abulseoud, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
  • Sondra Schultz, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All adult patients admitted for BMT or CAR-T therapy

Exclusion

Individuals unable to provide informed consent

What this trial measures

  • Prevalence of cannabis withdrawalUp to 1 year

    Descriptive statistics will be utilized to summarize cannabis withdrawal prevalence.

  • Severity of withdrawal symptomsDaily for first 4 days of hospitalization

    Assessed by the Cannabis Withdrawal Scale (CWS), a self-report instrument used measures the intensity of 19 cannabis withdrawal symptoms over the last 24 hours. Each item is rated on a 10-point Likert scale where 0=not al all and 10=extremely. Items are rated twice, first for intensity of symptom and then for negative impact on daily activity. Withdrawal symptom scores range from 0 to 190, with higher scores reflecting greater intensity of withdrawal symptoms.